← Leaderboards
Qing Yi
Methodist Hospital Research Institute
$20,966,577
Attributed
$21,357,102
Total exposure
16
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,357,102 · 16
By mechanism
R01$20,126,274 · 14
P50$1,230,828 · 2
Top collaborators
- Yong-Jun Liu3 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMalignant NeoplasmsTumorMultiple MyelomaNeoplastic CellIn VivoResponseMediatingT-LymphocyteMouse ModelIn VitroPharmaceutical PreparationsChemotherapyCancer TherapyBone MarrowPlasma CellsReportingCell LineReceptorTumor MicroenvironmentImmuneScid-Hu MiceBoneMalignant - Descriptor
Grant awards (69)
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors$489,857
R01 · FY2025 · CA · contact PI
Role of lipid metabolism in CD8+ T cell ferroptosis$484,536
R01 · FY2025 · CA · contact PI
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells$473,214
R01 · FY2025 · CA · contact PI
Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy$472,355
R01 · FY2025 · CA · contact PI
Tumor-specific CD8+ Tc9 cells activate host CD4+ T cells to control antigen-lost tumors$489,857
R01 · FY2024 · CA · contact PI
Exploring the role and potential of anti-viral drugs to sensitize cancer cells to chemotherapy$472,355
R01 · FY2024 · CA · contact PI
Role of lipid metabolism in CD8+ T cell ferroptosis$460,310
R01 · FY2024 · CA · contact PI
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells$449,554
R01 · FY2024 · CA · contact PI
Role of lipid metabolism in CD8+ T cell ferroptosis$484,536
R01 · FY2023 · CA · contact PI
Novel mechanism of induction of tumor pyroptosis by IL-9-secreting Tc9 cells$473,214
R01 · FY2023 · CA · contact PI
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion$417,003
R01 · FY2023 · CA · contact PI
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion$417,003
R01 · FY2022 · CA · contact PI
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion$425,512
R01 · FY2021 · CA · contact PI
Role of MIF in myeloma bone homing and drug response$369,431
R01 · FY2021 · CA · contact PI
Targeting macrophages to sensitize myeloma to immune checkpoint blockade$335,113
R01 · FY2021 · CA · contact PI
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion$425,512
R01 · FY2020 · CA · contact PI
Role of MIF in myeloma bone homing and drug response$369,431
R01 · FY2020 · CA · contact PI
A novel T-cell subset able to kill relapsed cancers$369,431
R01 · FY2020 · CA · contact PI
Targeting macrophages to sensitize myeloma to immune checkpoint blockade$335,113
R01 · FY2020 · CA · contact PI
Role of tumor microenvironment-derived cholesterol in CD8+ T-cell exhaustion$425,512
R01 · FY2019 · CA · contact PI
Role of MIF in myeloma bone homing and drug response$358,349
R01 · FY2019 · CA · contact PI
A novel T-cell subset able to kill relapsed cancers$358,347
R01 · FY2019 · CA · contact PI
Targeting macrophages to sensitize myeloma to immune checkpoint blockade$325,059
R01 · FY2019 · CA · contact PI
Role of MIF in myeloma bone homing and drug response$362,569
R01 · FY2018 · CA · contact PI
Targeting macrophages to sensitize myeloma to immune checkpoint blockade$328,888
R01 · FY2018 · CA · contact PI
A novel T-cell subset able to kill relapsed cancers$326,231
R01 · FY2018 · CA · contact PI
A novel T-cell subset able to kill relapsed cancers$42,397
R01 · FY2018 · CA · contact PI
Role of MIF in myeloma bone homing and drug response$362,569
R01 · FY2017 · CA · contact PI
A novel T-cell subset able to kill relapsed cancers$362,569
R01 · FY2017 · CA · contact PI
Targeting macrophages to sensitize myeloma to immune checkpoint blockade$328,888
R01 · FY2017 · CA · contact PI
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma$395,129
R01 · FY2016 · CA · contact PI
A novel T-cell subset able to kill relapsed cancers$362,569
R01 · FY2016 · CA · contact PI
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma$395,129
R01 · FY2015 · CA · contact PI
Mechanisms of Processivity in Molecular Motors$314,000
R01 · FY2015 · GM · contact PI
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma$383,275
R01 · FY2014 · CA · contact PI
C-reactive protein promotes myeloma cell-mediated bone destruction$348,132
R01 · FY2014 · CA · contact PI
P2 - ANTI-B2-MICR0GL0BULIN ANTIBODIES AS THERAPEUTIC AGENTS FOR MULTIPLE MYELOMA$171,549
P50 · FY2014 · CA · contact PI
Animals Models Core$60,338
P50 · FY2014 · CA · contact PI
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma$268,513
R01 · FY2013 · CA · contact PI
C-reactive protein promotes myeloma cell-mediated bone destruction$242,166
R01 · FY2013 · CA · contact PI
Targeting surface b2M for myeloma and bone therapy$208,706
R01 · FY2013 · CA · contact PI
P2 - ANTI-B2-MICR0GL0BULIN ANTIBODIES AS THERAPEUTIC AGENTS FOR MULTIPLE MYELOMA$181,783
P50 · FY2013 · CA · contact PI
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma$102,908
R01 · FY2013 · CA · contact PI
C-reactive protein promotes myeloma cell-mediated bone destruction$91,332
R01 · FY2013 · CA · contact PI
Targeting surface b2M for myeloma and bone therapy$88,755
R01 · FY2013 · CA · contact PI
Animals Models Core$71,968
P50 · FY2013 · CA · contact PI
Targeting Plasmacytoid Dendritic Cells to Treat Human Myeloma$409,629
R01 · FY2012 · CA · contact PI
C-reactive protein promotes myeloma cell-mediated bone destruction$357,767
R01 · FY2012 · CA · contact PI
Targeting surface b2M for myeloma and bone therapy$316,448
R01 · FY2012 · CA · contact PI
P2 - ANTI-B2-MICR0GL0BULIN ANTIBODIES AS THERAPEUTIC AGENTS FOR MULTIPLE MYELOMA$183,820
P50 · FY2012 · CA · contact PI
Animals Models Core$72,775
P50 · FY2012 · CA · contact PI
C-reactive protein promotes myeloma cell-mediated bone destruction$357,767
R01 · FY2011 · CA · contact PI
P2 - ANTI-B2-MICR0GL0BULIN ANTIBODIES AS THERAPEUTIC AGENTS FOR MULTIPLE MYELOMA$173,940
P50 · FY2011 · CA · contact PI
Animals Models Core$68,865
P50 · FY2011 · CA · contact PI
Targeting surface b2M for myeloma and bone therapy$319,552
R01 · FY2010 · CA · contact PI
P2 - ANTI-B2-MICR0GL0BULIN ANTIBODIES AS THERAPEUTIC AGENTS FOR MULTIPLE MYELOMA$181,720
P50 · FY2010 · CA · contact PI
C-reactive protein promotes myeloma cell-mediated bone destruction$163,925
R01 · FY2010 · CA · contact PI
Animals Models Core$64,070
P50 · FY2010 · CA · contact PI
Targeting surface b2M for myeloma and bone therapy$319,552
R01 · FY2009 · CA · contact PI
Optimizing Dendritic Cell Immunotherapy in Myeloma$277,385
R01 · FY2008 · CA · contact PI
Optimizing Dendritic Cell Immunotherapy in Myeloma$277,385
R01 · FY2007 · CA · contact PI
Idiotype-specific effector T cells in multiple myeloma$295,271
R01 · FY2006 · CA · contact PI
Optimizing Dendritic Cell Immunotherapy in Myeloma$285,669
R01 · FY2006 · CA · contact PI
Idiotype-specific effector T cells in multiple myeloma$302,378
R01 · FY2005 · CA
Optimizing Dendritic Cell Immunotherapy in Myeloma$292,543
R01 · FY2005 · CA
Idiotype-specific effector T cells in multiple myeloma$292,365
R01 · FY2004 · CA
Optimizing Dendritic Cell Immunotherapy in Myeloma$283,179
R01 · FY2004 · CA
Idiotype-specific effector T cells in multiple myeloma$292,365
R01 · FY2003 · CA
Idiotype-specific effector T cells in multiple myeloma$287,765
R01 · FY2002 · CA